Summary
26 breast cancer patients with recurrent disease were studied in order to evaluate whether transfer factor (TF) could abrogate serum blocking factors (SBF) and transfer or amplify immune reactivity directed to tumor-associated antigens (TAA) by using the leukocyte adherence inhibition assay (LAI). When 11 leukocyte samples obtained from patients reactive to cancer extract were preincubated with autologous blocking sera in the presence of PBS, nonspecific TF, or specific TF, leukocytes from these patients gained reactivity against breast cancer extract in none out of 11, one out of 11, and nine out of 11 experiments, respectively. Specific TF was obtained from donors with positive LAI breast cancer extract. Mean percentage LAI differences between control extract and breast cancer extract were −4.5±2.6, 0.5±1.7, and 15.5±2.4. The results of specific TF were significantly different from those of nonspecific TF (P<0.005).
When nine leukocyte samples obtained from patients unreactive to cancer extract were preincubated with autologous blocking sera in the presence of PBS, nonspecific TF, or specific TF, leukocytes from these patients gained reactivity against breast cancer extract in none out of nine, one out of nine, and seven out of nine experiments, respectively. Mean percentage LAI differences between control extract and breast cancer extract were −4.6±2.0, 0.6±2.3, and 11.8±3.5. The results of specific TF were again significantly different from those of nonspecific TF (P<0.005).
When allogeneic blocking sera were utilized, similar results were obtained. When specific TF was administered in two doses, 1 week apart subcutaneously to six breast cancer patients who were unreactive to breast cancer extracts, four patients gained reactivity against breast cancer extracts.
Our in vitro experiments support the presence of a specific component in transfer factor extract which can transfer or amplify cell-mediated reactivity with abrogation of SBF directed at TAA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BSS =:
-
Balanced Salt Solution
- LAI =:
-
Leukocyte Adherence Inhibition
- PBS =:
-
Phosphate Buffered Saline
- RPMI =:
-
Roswell Park Memorial Institute
- SBF =:
-
Serum Blocking Factors
- TAA =:
-
Tumor Associated Antigen
- TF =:
-
Transfer Factor
References
Brandes, L. J., Galton, D. A. G., Wiltshaw, E.: New approach to immunotherapy of melanoma. Lancet 1971 II, 293
Brandes, L. J., Goldenberg, G. J.: In vitro transfer of cellular immunity against nasopharyngeal carcinoma using transfer factor from donors with Epstein-Barr virus antibody activity. Cancer Res. 34, 3095 (1974)
Bullock, W. E., Fields, J., Brandriss, M.: Transfer factor therapy in leprotamous leprosy: An evaluation: J. clin. Invest. 50, 16a (Abstr. 51) (1971)
Burger, D. R., Vandenbark, A. A., Daves, D., Anderson, W. A., Vetto, R. M., Finke, P.: Human transfer factor: Fractionation and biologic activity. J. Immunol. 117, 789 (1976)
Currie, G. A., Basham, C.: Serum mediated inhibition of the immunological reactions of the patient to his own tumor: A possible role for circulating antigen. Brit. J. Cancer 26, 427 (1972)
Fujisawa, T., Waldman, S. R., Yonemoto, R. H.: Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients. Cancer 39, 134 (1977)
Fujisawa, T., Waldman, S. R., Yonemoto, R. H.: Demonstration of blocking factors on leukocyte adherence inhibition and lymphocyte blastogenesis in sera of breast cancer patients. Arch. Surg. (in press, 1978)
Halliday, W. J., Miller, S.: Leukocyte adherence inhibition: A simple test for cell-mediated tumor immunity and serum blocking factors. Int. J. Cancer 9, 477 (1972)
Hamblin, A. S., Maini, R. N., Dumonde, D. C.: Human transfer factor in vitro. I. Augmentation of lymphocyte transformation to tuberculin PPD. Clin. exp. Immunol. 23, 290 (1976)
Lawrence, H. S.: The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes. J. clin. Invest. 34, 219 (1955)
Lawrence, H. S.: Transfer Factor. Advanc. Immunol. 11, 195 (1969)
Lawrence, H. S., Al-Askari, S.: The preparation and purification of Transfer Factor. In: In vitro Methods in Cell-mediated Immunity. (Bloom, B. R., Glade, P. R., eds.), pp. 531–536. New York: Academic Press 1971
Lawrence, H. S., Zweiman, B.: Transfer factor deficiency response — A mechanism of anergy in Boeck's sarcoid. Trans. Ass. Amer. Phycns 81, 240 (1968)
Levin, A. S., Byers, V. S., Fudenberg, H. H., Wybran, J., Hackett, A. J., Johnston, J. O., Spitler, L. E.: Osteogenic sarcoma, immunologic parameters before and during immunotherapy with tumor-specific transfer factor. J. clin. Invest. 55, 487 (1975)
Levin, A. S., Spitler, L. E., Stites, D. P., Fudenberg, H. H.: Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: Clinical and laboratory responses to therapy with transfer factor. Proc. nat. Acad. Sci. (Wash.) 67, 821 (1970)
Lo Buglio, A. F., Neidhart, J. A., Hilberg, R. W., Metz, E. N., Balcerzak, S. P.: The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma. Cell. Immunol. 7, 159 (1973)
Lowry, O. H., Rosebrough, N. J., Farr, A. Z., Randall, R. J.: Protein measurement with the folin phenol reagent. J. biol. Chem. 193, 265 (1951)
Maluish, A., Halliday, W. J.: Cell-mediated immunity and specific serum factors in human cancer: The leukocyte adherence inhibition test. J. nat. Cancer Inst. 52, 1415 (1974)
Meltzer, M. S., Leonard, E. J., Rapp, H. J., Borsos, T.: Tumorspecific antigen solubilized by hypertonic potassium chloride. J. nat. Cancer Inst. 47, 703 (1971)
Oettgen, H., Old, L., Farrow, J., Valentine, F., Lawrence, S., Thomas, L.: Effects of transfer factor in cancer patients. J. clin. Invest. 50, 71a (Abstr. 239) (1971)
Paque, R. E., Dray, S., Kniskern, P., Baram, P.: In vitro studies with “Transfer Factor”. II. Transfer of the cell-migration inhibition correlate of delayed hypersensitivity in humans with nondialyzable components of leukocyte lysates from humans sensitized to histoplasmin and coccidioidin. Cell. Immunol. 6, 368 (1973)
Rich, R. R., Kirkpatrick, C. H., Smith, T. K.: Pathogenetic and therapeutic correlations in chronic mucocutaneous candidiasis. J. clin. Invest. 51, 78a (Abstr. 259) (1972)
Vetto, R. M., Burger, D. R., Nolte, J. E., Vandenbark, A. A., Baker, H. W.: Transfer factor therapy in patients with cancer. Cancer 37, 90 (1976)
Waldman, S. R., Roth, J. A., Silverstein, M., Veltman, L. L., Pilch, Y. H.: Effects on cancer patients of leukapheresis with the continuous flow blood cell separator. I. Hematologic and immunologic parameters in vivo. J. Lab. clin. Med. 86, 938 (1975)
Waldman, S. R., Roth, J. A., Kern, D. H., Pilch, Y. H.: Effects on cancer patients of leukapheresis with the continuous flow blood cell separator. II. Immunologic parameters in vitro. J. Lab. clin. Med. 86, 950 (1975)
Yonemoto, R. H., Fujisawa, T., Waldman, S. R.: Effect of serum blocking factors on leukocyte adherence inhibition in breast cancer patients: Specificity and correlation with tumor burden. Cancer 4, 1289–1297 (1978)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fujisawa, T., Waldman, S.R. & Yonemoto, R.H. Transfer factor in vitro abrogation of blocking factors and amplification of immunoreactivity directed to soluble tumor associated antigens in the leukocyte adherence inhibition assay. Cancer Immunol Immunother 4, 77–86 (1978). https://doi.org/10.1007/BF00200107
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00200107